KOPRAN
vs
B
BSE Sensex 30
KOPRAN
Over the past 12 months, KOPRAN has underperformed BSE Sensex 30, delivering a return of -41% compared to the BSE Sensex 30's +9% growth.
Stocks Performance
KOPRAN vs BSE Sensex 30
Performance Gap
KOPRAN vs BSE Sensex 30
Performance By Year
KOPRAN vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kopran Ltd
Glance View
Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing and supplying international formulations (Finished Dosage Form) and active pharmaceutical ingredients (APIs). Its formulation business unit manufactures oral solid dosages and dry powder formulations for both penicillin and non-penicillin-based drugs. Its APIs business unit offers Sterile Cephalosporins and Carbapenems. The company also offers Macrolide, Antibacterial, Anticonvulsant, and Cardiovascular range of drugs. Its product offering includes antibiotics, cardiovascular, antidiabetic, gastrointestinal, pain management, drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, and anthelmintics. Its antibiotics brands include AMPIK 250 / 500, AMPIK SYRUP, and AMYN - 250 / 500. Its cardiovascular brands include CARDIOTEN - 25 / 50 / 100, CADITONE - 3.125 / 6.25 / 12.5 / 25 and KLODIP - 5 / 10.
